Profile for Taiwan Patent: 200534860

US Patent Family Members and Approved Drugs for Taiwan Patent: 200534860

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
8,071,577	May 13, 2026	Bayer Hlthcare	NATAZIA	dienogest; estradiol valerate

Taiwan Patent TW200534860: Scope, Claims, and Patent Landscape

Last updated: April 30, 2026

What does Taiwan patent TW200534860 claim at the technical and legal level?

The requested patent dossier for TW200534860 is not present in the information provided in this chat. Without the patent’s bibliographic record (publication/application details), full text (specification + claims), and prosecution data (family members and claim amendments), a complete and accurate claim-scope and landscape cannot be produced under the constraints of this task.

What is the claim scope and what would it cover in practice?

A claim-scope analysis requires the actual independent and dependent claim text, including:

• active ingredient(s) and chemical structure definitions (Markush groups, salts, hydrates, solvates)
• formulation types (dosage forms, excipients)
• process claims (manufacturing parameters, catalysts, intermediates)
• therapeutic use (indications, dosing regimens)
• claim construction cues (terms defined in the spec, priority dates, embodiment language)

No claim text for TW200534860 is available here.

How does TW200534860 sit in the Taiwan and global patent landscape?

A landscape requires, at minimum:

• the patent family (WO/EP/US/CN publication equivalents)
• key competitors and closest prior art patents (composition, method-of-treatment, process)
• status in Taiwan (granted/expired/withdrawn, term adjustments)
• claim overlap mapping against likely generic entry strategies

No family mapping or status data for TW200534860 is available in this chat.

What freedom-to-operate conclusions can be drawn from TW200534860?

Freedom-to-operate conclusions require:

• the exact claim breadth (especially for Markush definitions and method-of-treatment language)
• co-pending or earlier filings that can narrow interpretation
• expiration and enforcement posture in Taiwan

No such data is available here.

What can be provided in place of a complete analysis?

Nothing can be provided accurately, because the operative inputs (claims/specifications and bibliographic/publication identifiers) are missing.

---

Key Takeaways

• TW200534860 cannot be analyzed for scope, claim coverage, or landscape without the patent’s claim/specification text and family/status data.
• A reliable Taiwan drug patent landscape requires publication equivalents, claim charts, and status, none of which are present here.
• Any attempt to produce scope or landscape from partial or assumed information would fail the requirement for completeness and accuracy.

---

FAQs

1. Can you summarize TW200534860’s independent claims without the claim text?
   No.

2. Can you map TW200534860 to global filings without family identifiers?
   No.

3. Can you estimate Taiwan claim expiration or term without status/filing dates?
   No.

4. Can you assess generic design-around options without knowing the Markush groups and method-of-treatment language?
   No.

5. Can you provide competitor and prior-art citations without seeing the patent’s own citations and family?
   No.

---

References

[1] No citable sources were provided in the prompt for TW200534860.